Country: United States
Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated
biopharmaceutical company, which finds out, creates, builds up, manufactures,
and commercializes medicines for the treatment of serious medical conditions.
As of December 31, 2011, the Company had two marketed products: EYLEA
(aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous
Use. As of December 31, 2011, the Company had 13 product
candidates in clinical growth. Its Trap-based, late-stage programs are EYLEA,
which is being developed for the action of additional serious eye diseases;
ZALTRAP (aflibercept), known in the scientific literature as vascular
endothelial increase factor (VEGF) trap, which is being developed in oncology
in teamwork with Sanofi; and ARCALYST, which is being developed for the
prevention of gout flares in patients initiating uric acid-lowering treatment.
